Alain Beck is Senior Director of Analytical Chemistry, New Biological Entities, at the Center of Immunology Pierre Fabre (FR) and associated editor of mAbs (USA). He has contributed to the R&D of clinical stages anticancer mAbs and ADCs (dalotuzumab licensed to Merck, telisotuzumab vedotin licensed to AbbVie and h515H7) and vaccines (RSV, ELA/P40). He has published 176 papers and reports on mAbs, biosimilars, biobetters, ADCs, bsAbs, Fc-fusion structures/functions relationships and developability. He was involved in more than 230 scientific meetings (AIS, ASMS, BAS, EAC, HPLC, IBC, IMSC PEGS, SEP, WADC, WBC) as chairperson, invited speaker, panelist, moderator, advisor, and organizer as well as meetings with regulatory agencies (ANSM, EMA, EDQM, FDA, PEI, WHO).